Barclays PLC Buys 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Barclays PLC grew its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 390.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 41,684 shares of the company’s stock after purchasing an additional 33,185 shares during the period. Barclays PLC’s holdings in Dianthus Therapeutics were worth $1,141,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in DNTH. Quest Partners LLC lifted its position in Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Dianthus Therapeutics in the second quarter valued at approximately $236,000. SG Americas Securities LLC boosted its position in shares of Dianthus Therapeutics by 104.0% during the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock valued at $242,000 after buying an additional 4,506 shares during the last quarter. Fred Alger Management LLC grew its holdings in Dianthus Therapeutics by 52.5% during the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after buying an additional 3,316 shares in the last quarter. Finally, WINTON GROUP Ltd bought a new stake in Dianthus Therapeutics during the second quarter worth $265,000. Institutional investors own 47.53% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. TD Cowen initiated coverage on Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating on the stock. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Finally, Oppenheimer boosted their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $46.43.

Dianthus Therapeutics Stock Performance

DNTH stock opened at $23.04 on Tuesday. The stock has a fifty day moving average of $24.48 and a 200-day moving average of $26.61. Dianthus Therapeutics, Inc. has a fifty-two week low of $10.65 and a fifty-two week high of $33.77. The company has a market capitalization of $681.91 million, a price-to-earnings ratio of -9.22 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.